RS
ATRA icon

Ricky Sandler’s Atara Biotherapeutics ATRA Stock Holding History

Ricky Sandler’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-52,923
Closed -$10.3M – 64
2022
Q2 		$10.3M Sell
52,923
-1,785
-3% -$291K 0.2% 59
2022
Q1 		$12.7M Buy
54,708
+9,050
+20% +$2.88M 0.14% 59
2021
Q4 		$18M Buy
+45,658
New +$19.2M 0.17% 62

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ricky Sandler's ATRA Position: Q3 2022 in Review

Ricky Sandler sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 52,923 shares — an estimated $10.3M sold.

Ricky Sandler first reported a position in ATRA in Q4 2021 and held it in 3 quarters. The position peaked at $18M in Q4 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Ricky Sandler reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Ricky Sandler sold 52,923 Atara Biotherapeutics shares in Q3 2022, an estimated $10.3M.
  • Ricky Sandler first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Ricky Sandler's Atara Biotherapeutics position peaked at $18M in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Eminence Capital's 13F filing for Q3 2022, filed 14 Nov 2022.